Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis

Abstract

Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk (RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53 mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to 23.4 with a combined RH estimate of 2.0 (confidence interval 1.7-2.5). Three studies investigated the role of p53 in node-negative patients and in these, the combined estimate of RH was 1.7 (1.2-2.3). For three studies of node-positive breast cancer the combined risk estimate was 2.6 (1.7-3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results. Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in prognostication, and possibly choice of therapy.

References 35

1. 1.

   Aas T., Børresen A. L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lønning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996;2(7):811-814.

   Not in our library10.1038/nm0796-811

2. 2.

   Allred D. C., Clark G. M., Elledge R., Fuqua S. A., Brown R. W., Chamness G. C., Osborne C. K., McGuire W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85(3):200-206.

   Not in our library10.1093/jnci/85.3.200

3. 3.

   Andersen T. I., Holm R., Nesland J. M., Heimdal K. R., Ottestad L., Børresen A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 1993;68(3):540-548.

   Not in our library10.1038/bjc.1993.383

4. 4.

   Barnes D. M., Dublin E. A., Fisher C. J., Levison D. A., Millis R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol. 1993;24(5):469-476.

   Not in our library10.1016/0046-8177(93)90158-d

5. 5.

   Beck T., Weller E. E., Weikel W., Brumm C., Wilkens C., Knapstein P. G. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol. 1995;57(1):96-104.

   Not in our library10.1006/gyno.1995.1104

6. 6.

   Bergh J., Norberg T., Sjögren S., Lindgren A., Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1(10):1029-1034.

   Not in our library10.1038/nm1095-1029

7. 7.

   Berns E. M., van Staveren I. L., Look M. P., Smid M., Klijn J. G., Foekens J. A. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer. 1998;77(7):1130-1136.

   Not in our library10.1038/bjc.1998.187

8. 8.

   Bianchi S., Calzolari A., Vezzosi V., Zampi G., Cardona G., Cataliotti L., Bonardi R., Ciatto S. Lack of prognostic value of p53 protein expression in node-negative breast cancer. Tumori. 1997;83(3):669-672.

   Not in our library10.1177/030089169708300309

9. 9.

   Børresen A. L., Andersen T. I., Eyfjörd J. E., Cornelis R. S., Thorlacius S., Borg A., Johansson U., Theillet C., Scherneck S., Hartman S. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 1995;14(1):71-75.

   Not in our library10.1002/gcc.2870140113

10. 10.

    Caleffi M., Teague M. W., Jensen R. A., Vnencak-Jones C. L., Dupont W. D., Parl F. F. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer. 1994;73(8):2147-2156.

    Not in our library10.1002/1097-0142(19940415)73:8<2147::aid-cncr2820730820>3.0.co;2-5

11. 11.

    Egger M., Smith G. D. Misleading meta-analysis. BMJ. 1995;310(6982):752-754.

    Not in our library10.1136/bmj.310.6982.752

12. 12.

    Elledge R. M., Clark G. M., Fuqua S. A., Yu Y. Y., Allred D. C. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res. 1994;54(14):3752-3757.

    Not in our library

13. 13.

    Elledge R. M., Fuqua S. A., Clark G. M., Pujol P., Allred D. C., McGuire W. L. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat. 1993;26(3):225-235.

    Not in our library10.1007/bf00665800

14. 14.

    Falette N., Paperin M. P., Treilleux I., Gratadour A. C., Peloux N., Mignotte H., Tooke N., Löfman E., Inganäs M., Bremond A. Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res. 1998;58(7):1451-1455.

    Not in our library

15. 15.

    Gretarsdottir S., Tryggvadottir L., Jonasson J. G., Sigurdsson H., Olafsdottir K., Agnarsson B. A., Ogmundsdottir H., Eyfjörd J. E. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer. 1996;74(4):555-561.

    Not in our library10.1038/bjc.1996.400

16. 16.

    Göhring U. J., Scharl A., Heckel C., Ahr A., Crombach G. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet. 1995;256(3):139-146.

    Not in our library10.1007/bf01314642

17. 17.

    Hartmann A., Blaszyk H., Kovach J. S., Sommer S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet. 1997;13(1):27-33.

    Not in our library10.1016/s0168-9525(96)10043-3

18. 18.

    Iacopetta B., Grieu F., Powell B., Soong R., McCaul K., Seshadri R. Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res. 1998;4(7):1597-1602.

    Not in our library

19. 19.

    Isola J., Visakorpi T., Holli K., Kallioniemi O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992;84(14):1109-1114.

    Not in our library10.1093/jnci/84.14.1109

20. 20.

    Jansson T., Inganäs M., Sjögren S., Norberg T., Lindgren A., Holmberg L., Bergh J. p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol. 1995;13(11):2745-2751.

    Not in our library10.1200/jco.1995.13.11.2745

21. 21.

    Kovach J. S., Hartmann A., Blaszyk H., Cunningham J., Schaid D., Sommer S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci U S A. 1996;93(3):1093-1096.

    Not in our library10.1073/pnas.93.3.1093

22. 22.

    Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15-16.

    Not in our library10.1038/358015a0

23. 23.

    Levesque M. A., Katsaros D., Yu H., Giai M., Genta F., Roagna R., Ponzone R., Massobrio M., Sismondi P., Diamandis E. P. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. Int J Cancer. 1998;79(2):147-152.

    Not in our library10.1002/(sici)1097-0215(19980417)79:2<147::aid-ijc9>3.0.co;2-t

24. 24.

    Lipponen P., Ji H., Aaltomaa S., Syrjänen S., Syrjänen K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer. 1993;55(1):51-56.

    Not in our library10.1002/ijc.2910550110

25. 25.

    Norberg T., Lennerstrand J., Inganäs M., Bergh J. Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer. 1998;79(4):376-383.

    Not in our library10.1002/(sici)1097-0215(19980821)79:4<376::aid-ijc12>3.0.co;2-3

26. 26.

    Riou G., Lê M. G., Travagli J. P., Levine A. J., Moll U. M. Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. J Natl Cancer Inst. 1993;85(21):1765-1767.

    Not in our library10.1093/jnci/85.21.1765

27. 27.

    Seshadri R., Leong A. S., McCaul K., Firgaira F. A., Setlur V., Horsfall D. J. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer. 1996;69(2):135-141.

    Not in our library10.1002/(sici)1097-0215(19960422)69:2<135::aid-ijc12>3.0.co;2-8

28. 28.

    Shiao Y. H., Chen V. W., Scheer W. D., Wu X. C., Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res. 1995;55(7):1485-1490.

    Not in our library

29. 29.

    Silvestrini R., Benini E., Daidone M. G., Veneroni S., Boracchi P., Cappelletti V., Di Fronzo G., Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993;85(12):965-970.

    Not in our library10.1093/jnci/85.12.965

30. 30.

    Soong R., Iacopetta B. J., Harvey J. M., Sterrett G. F., Dawkins H. J., Hahnel R., Robbins P. D. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer. 1997;74(6):642-647.

    Not in our library10.1002/(sici)1097-0215(19971219)74:6<642::aid-ijc15>3.0.co;2-7

31. 31.

    Stenmark-Askmalm M., Stål O., Sullivan S., Ferraud L., Sun X. F., Carstensen J., Nordenskjöld B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur J Cancer. 1994;30A(2):175-180.

    Not in our library10.1016/0959-8049(94)90082-5

32. 32.

    Thor A. D., Moore DH I. I., Edgerton S. M., Kawasaki E. S., Reihsaus E., Lynch H. T., Marcus J. N., Schwartz L., Chen L. C., Mayall B. H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84(11):845-855.

    Not in our library10.1093/jnci/84.11.845

33. 33.

    Thorlacius S., Thorgilsson B., Björnsson J., Tryggvadottir L., Börresen A. L., Ogmundsdottir H. M., Eyfjörd J. E. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. Eur J Cancer. 1995;31A(11):1856-1861.

    Not in our library10.1016/0959-8049(95)00399-4

34. 34.

    Tsuda H., Sakamaki C., Tsugane S., Fukutomi T., Hirohashi S. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases. Breast Cancer Res Treat. 1998;48(1):21-32.

    Not in our library10.1023/a:1005977630830

35. 35.

    Valgardsdottir R., Tryggvadottir L., Steinarsdottir M., Olafsdottir K., Jonasdottir S., Jonasson J. G., Ogmundsdottir H. M., Eyfjörd J. E. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS. 1997;105(2):121-130.

    Not in our library10.1111/j.1699-0463.1997.tb00550.x

Cited by papers we hold 5

• Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA · 2020
  Not checked
• Household income is associated with the p53 mutation frequency in human breast tumors. · 2013
  Not checked
• TP53mutation status and gene expression profiles are powerful prognostic markers of breast cancer · 2007
  No notice
• Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 · 2006
  No notice
• Gene expression patterns associated with p53 status in breast cancer · 2006
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.